So, here we are, launching our fourth edition of Fierce Biotech's layoff tracker. As always, if you know of a layoff occurring at a biotech, please reach out to the Fierce Biotech editorial team ...

These names in the biotech sector are seeing a substantial ... in advanced cancer should proceed to cohort 5, 22mg capsule, without modification. This recommendation was based on the review ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Pipeline and key clinical candidates for these ...

While 2024 was a “challenging” year for biotech stocks, JPMorgan is of the view that some names in the industry may be poised for considerable upside in the coming months. On November 28 ...

Merck's (NYSE:MRK) recent acquisition of rights to Chinese biotech LaNova Medicines' cancer candidate LM-299 in a deal worth up to $3.3B underscores Big Pharma's appetite for best-in-class assets ...

Biohazard sign on black background with diverging waves Biohazard sign on black background with animation effect and diverging waves biotech logo stock videos & royalty-free footage Genetic ...

They show that he plans to divest stock holdings, including stakes in biotech firms CRISPR Therapeutics AG and Dragonfly Therapeutics. He’s also stepping down from roles at his law firm and at ...

The BioXplorer 100 from H.E.L is a multi-bioreactor system that has been specifically developed for the optimization of aerobic fermentations. Having a working volume as low as 50 mL, the ...

But local biotech leaders see signs of change in 2025. Amid tough biotech industry market conditions last year, investors and Big Pharma companies were more likely to make deals with later-stage ...

Prolium was set up by RTW in 2024. Last year also saw the New York-based investment fund involved in the launch of obesity biotech Kailera Therapeutics, which RTW said at the time was the fourth ...

The biotech firm's mRNA-1018 candidate posted positive results in a Phase 1/2 study launched in 2023. Moderna plans to move mRNA-1018 to a Phase 3 trial. Shares of Moderna (MRNA) took off Tuesday ...